The World Health Organization is developing an Essential Diagnostics List, a document outlining important medical tests that will improve international health outcomes, and facilitate access to critical treatments and medications. Starting in 1977, WHO developed an Essential Medications List that is updated biannually. Many countries have adapted and amended this list for their own needs, then using it as a starting point for policies to control drug prices and availability. Canada has outlined the development of their Essential Medications list in an early 2017 publication in the Canadian Medical Associations Open Access Journal .
From the Huffington Post:
“There are many potential benefits to an EDL: improving patient care, helping detect outbreaks, increasing affordability of tests, reducing out-of-pocket expenses for tests, reducing antibiotic abuse, improving regulation and quality of diagnostic tests, strengthening accreditation and quality of laboratories, improving supply chain, and guiding the R&D of new diagnostic tools.
Thus, member states, as well as global health agencies, should applaud and support the decision by WHO to develop an EDL, and to create an advisory group on diagnostics. Both decisions demonstrate a serious commitment by WHO to recognize the importance of good diagnostics as a way of increasing the impact of essential medicines, and contributing to UHC”
Read the full article in the Huffington Post here .